By Liz Moyer
Investing.com -- Teladoc got a boost during the pandemic when people were doing most everything online, including seeing the doctor.
But increasing competition is creating a crowded field. Guggenheim analysts cut their rating of Teladoc Inc (NYSE:TDOC) to sell from neutral with a price target of $25, saying adjusted earnings and revenue growth would be pressured by its exposure to the consumer segment, which contributes 40% of sales.
Not all analysts agree. Just last week, D.A. Davidson started covering Teladoc with a buy rating and price target of $45, saying the company had “established itself” as a leader in telehealth.
Shares of Teladoc fell 8% on Wednesday and are down about 61% for the year.
Several larger competitors are casting a shadow over the primary care market. Amazon.com Inc (NASDAQ:AMZN) has a $4 billion deal to acquire One Medical, a primary care operator that offers telehealth.
CVS Health Corp (NYSE:CVS) also wants to move into primary care, once thought to be a suitor for One Medical and now thought to be looking to buy Signify Health Inc (NYSE:SGFY).
Walmart Inc (NYSE:WMT) operates nearly two-dozen health centers in its stores, including primary care. And rival Walgreens Boots Alliance Inc (NASDAQ:WBA) put $5 billion into primary care operator VillageMD in a deal last year.
There are also American Well Corp (NYSE:AMWL) and MDLive operating in the telehealth space. AmWell this month was chosen by CVS to operate its virtual primary care offering.
Shares of AmWell are down 22% this year.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.